Image

Melanoma Research

Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients”
06/30/2021

EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients

Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Blog - Melanoma360
Breaking News
Melanoma Research
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/30/2021

EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients

Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
Featured image for “EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/15/2021

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

  Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
Featured image for “Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
04/14/2021

Lifileucel Proves Efficacy in Pretreated Advanced Melanoma

  Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
Featured image for “Lifileucel Proves Efficacy in Pretreated Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/11/2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

  March 11, 2021 | Source: PRNewswire   DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Featured image for “FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research